HLB Therapeutics Co.,Ltd.: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 September 2022

  • curprev 12:4712:47, 22 September 2022 >Nick 828 bytes +828 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == HLB Therapeutics Co.,Ltd. develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmologic diseases, such as dry eye syndrome and neurotrophic keratopathy; GBT-101 for treating epidermolysis bullosa dermal disease; and OKN-007 for the treatment of glioblastoma brain cancer. It is also involved in the wholesale of vaccines, as well as manufa..."